Objective: We investigated the risk of AIDS and serious non-AIDS-defining diseases (non-ADDs)
according to the degree of immunological recovery after 2 years of virological …

Background Describing the SARS-CoV-2 viral-load distribution in different patient groups
and age categories. Methods All results from first nasopharyngeal (NP) and oropharyngeal (OP…

Background Long-acting (LA) injectable therapy with cabotegravir (CAB) and rilpivirine (RPV)
is currently used as maintenance treatment for human immunodeficiency virus type 1, and …

Background Understanding the dynamics of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) household transmission is important for adequate infection control …

The proteasome has been shown to make the proper C-terminal cleavage for the generation
of several immunodominant class I-presented peptides whereas aminopeptidases …

Objective The immunomodulatory effects of the CCR5-antagonist maraviroc might be
beneficial in patients with a suboptimal immunological response, but results of different cART (…

Background: In HIV infection, the homeostasis of CD4+ and CD8+ T cells is dramatically
disturbed, and several studies have pointed out that T-cell turnover rates are increased. To …

Background We assessed the association between severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) viral load and hospital admission, intensive care unit (ICU) …

Objectives Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor
antagonist in clinical practice. It is currently being used in patients harbouring exclusively CCR5-…

Mycoplasma pneumoniae is an important cause of pneumonia and extra-pulmonary
manifestations. We observed a rise in admissions due to M. pneumoniae infections starting October …